HMGB1 promotes drug resistance in osteosarcoma

Jun Huang, Jiangdong Ni, Ke Liu, Yan Yu, Min Xie, Rui Kang, Philip Vernon, Lizhi Cao, Daolin Tang

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Osteosarcoma is the most commonly occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common due to the development of chemoresistance, for which the underlying molecular mechanisms remain unclear. In this study, we implicate the DNA-binding protein HMGB1, which also exerts immunoregulatory effects in its secreted form, in the development of drug resistance in osteosarcoma. Anticancer agents including doxorubicin, cisplatin, and methotrexate each induced HMGB1 upregulation in human osteosarcoma cells, and RNA interference-mediated knockdown of HMGB1 restored the chemosensitivity of osteosarcoma cells in vivo and in vitro. Mechanistic investigation revealed that HMGB1 increased drug resistance by inducing autophagy, an intracellular self-defense mechanism known to confer drug resistance. We found that HMGB1 bound to the autophagy regulator Beclin1 and regulated the formation of the Beclin1-PI3KC3 [PI3KC3, phosphatidylinositol 3-kinase class 3] complex that facilitates autophagic progression. In addition, we found that interaction between HMGB1 and Beclin1 relied upon the autophagic complex ULK1-mAtg13-FIP200. Therefore, through its role as a regulator of autophagy, HMGB1 is a critical factor in the development of chemoresistance, and it offers a novel target for improving osteosarcoma therapy.

Original languageEnglish (US)
Pages (from-to)230-238
Number of pages9
JournalCancer Research
Volume72
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

HMGB1 Protein
Osteosarcoma
Drug Resistance
Autophagy
Phosphatidylinositol 3-Kinase
Bone Neoplasms
DNA-Binding Proteins
RNA Interference
Treatment Failure
Methotrexate
Antineoplastic Agents
Doxorubicin
Cisplatin
Up-Regulation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

HMGB1 promotes drug resistance in osteosarcoma. / Huang, Jun; Ni, Jiangdong; Liu, Ke; Yu, Yan; Xie, Min; Kang, Rui; Vernon, Philip; Cao, Lizhi; Tang, Daolin.

In: Cancer Research, Vol. 72, No. 1, 01.01.2012, p. 230-238.

Research output: Contribution to journalArticle

Huang, J, Ni, J, Liu, K, Yu, Y, Xie, M, Kang, R, Vernon, P, Cao, L & Tang, D 2012, 'HMGB1 promotes drug resistance in osteosarcoma', Cancer Research, vol. 72, no. 1, pp. 230-238. https://doi.org/10.1158/0008-5472.CAN-11-2001
Huang, Jun ; Ni, Jiangdong ; Liu, Ke ; Yu, Yan ; Xie, Min ; Kang, Rui ; Vernon, Philip ; Cao, Lizhi ; Tang, Daolin. / HMGB1 promotes drug resistance in osteosarcoma. In: Cancer Research. 2012 ; Vol. 72, No. 1. pp. 230-238.
@article{4b6a33af59a0461588aa5c2785fc80ce,
title = "HMGB1 promotes drug resistance in osteosarcoma",
abstract = "Osteosarcoma is the most commonly occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common due to the development of chemoresistance, for which the underlying molecular mechanisms remain unclear. In this study, we implicate the DNA-binding protein HMGB1, which also exerts immunoregulatory effects in its secreted form, in the development of drug resistance in osteosarcoma. Anticancer agents including doxorubicin, cisplatin, and methotrexate each induced HMGB1 upregulation in human osteosarcoma cells, and RNA interference-mediated knockdown of HMGB1 restored the chemosensitivity of osteosarcoma cells in vivo and in vitro. Mechanistic investigation revealed that HMGB1 increased drug resistance by inducing autophagy, an intracellular self-defense mechanism known to confer drug resistance. We found that HMGB1 bound to the autophagy regulator Beclin1 and regulated the formation of the Beclin1-PI3KC3 [PI3KC3, phosphatidylinositol 3-kinase class 3] complex that facilitates autophagic progression. In addition, we found that interaction between HMGB1 and Beclin1 relied upon the autophagic complex ULK1-mAtg13-FIP200. Therefore, through its role as a regulator of autophagy, HMGB1 is a critical factor in the development of chemoresistance, and it offers a novel target for improving osteosarcoma therapy.",
author = "Jun Huang and Jiangdong Ni and Ke Liu and Yan Yu and Min Xie and Rui Kang and Philip Vernon and Lizhi Cao and Daolin Tang",
year = "2012",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-11-2001",
language = "English (US)",
volume = "72",
pages = "230--238",
journal = "Cancer Research",
issn = "0008-5472",
number = "1",

}

TY - JOUR

T1 - HMGB1 promotes drug resistance in osteosarcoma

AU - Huang, Jun

AU - Ni, Jiangdong

AU - Liu, Ke

AU - Yu, Yan

AU - Xie, Min

AU - Kang, Rui

AU - Vernon, Philip

AU - Cao, Lizhi

AU - Tang, Daolin

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Osteosarcoma is the most commonly occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common due to the development of chemoresistance, for which the underlying molecular mechanisms remain unclear. In this study, we implicate the DNA-binding protein HMGB1, which also exerts immunoregulatory effects in its secreted form, in the development of drug resistance in osteosarcoma. Anticancer agents including doxorubicin, cisplatin, and methotrexate each induced HMGB1 upregulation in human osteosarcoma cells, and RNA interference-mediated knockdown of HMGB1 restored the chemosensitivity of osteosarcoma cells in vivo and in vitro. Mechanistic investigation revealed that HMGB1 increased drug resistance by inducing autophagy, an intracellular self-defense mechanism known to confer drug resistance. We found that HMGB1 bound to the autophagy regulator Beclin1 and regulated the formation of the Beclin1-PI3KC3 [PI3KC3, phosphatidylinositol 3-kinase class 3] complex that facilitates autophagic progression. In addition, we found that interaction between HMGB1 and Beclin1 relied upon the autophagic complex ULK1-mAtg13-FIP200. Therefore, through its role as a regulator of autophagy, HMGB1 is a critical factor in the development of chemoresistance, and it offers a novel target for improving osteosarcoma therapy.

AB - Osteosarcoma is the most commonly occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common due to the development of chemoresistance, for which the underlying molecular mechanisms remain unclear. In this study, we implicate the DNA-binding protein HMGB1, which also exerts immunoregulatory effects in its secreted form, in the development of drug resistance in osteosarcoma. Anticancer agents including doxorubicin, cisplatin, and methotrexate each induced HMGB1 upregulation in human osteosarcoma cells, and RNA interference-mediated knockdown of HMGB1 restored the chemosensitivity of osteosarcoma cells in vivo and in vitro. Mechanistic investigation revealed that HMGB1 increased drug resistance by inducing autophagy, an intracellular self-defense mechanism known to confer drug resistance. We found that HMGB1 bound to the autophagy regulator Beclin1 and regulated the formation of the Beclin1-PI3KC3 [PI3KC3, phosphatidylinositol 3-kinase class 3] complex that facilitates autophagic progression. In addition, we found that interaction between HMGB1 and Beclin1 relied upon the autophagic complex ULK1-mAtg13-FIP200. Therefore, through its role as a regulator of autophagy, HMGB1 is a critical factor in the development of chemoresistance, and it offers a novel target for improving osteosarcoma therapy.

UR - http://www.scopus.com/inward/record.url?scp=84855406005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855406005&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2001

DO - 10.1158/0008-5472.CAN-11-2001

M3 - Article

C2 - 22102692

AN - SCOPUS:84855406005

VL - 72

SP - 230

EP - 238

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 1

ER -